PMID: 11341359May 9, 2001Paper

Improvement in site-specific intestinal absorption of furosemide by Eudragit L100-55

The Journal of Pharmacy and Pharmacology
T TeraoH Shouji

Abstract

Furosemide (frusemide) is a weakly acidic diuretic drug. Its absorption is poor and variable, in part due to its restricted sites of absorption, mainly the stomach. The narrow absorption window of this drug can be explained by pH partition theory. The purpose of this study was to investigate the feasibility of widening the absorption window of furosemide by controlling the pH in distal portions of the gastrointestinal tract with officially used additives. Methacrylate copolymer (Eudragit L100-55), hydroxypropylmethylcellulose phthalate (HP-55) and hydroxypropylmethylcellulose acetate succinate (AS-MF) were selected as additives. The pH of suspensions of these additives was about 4, and the pH was adjusted to about 6-7 by the addition of NaOH. The Eudragit L100-55 suspension was found to be the most resistant to NaOH titration. When Eudragit L100-55 was used in an in-situ ileal loop experiment in rats, the pH of the intestinal contents was significantly reduced, from 7.9+/-0.1 to 5.7+/-0.1, and the plasma concentration of furosemide 15 min after administration was about 3 times higher than that in controls, 1.81+/- 0.42microg mL(-1) vs 0.63+/-0.08 microg mL(-1). However, the plasma concentration of [14C] mannitol was not changed...Continue Reading

References

Feb 1, 1979·Journal of Pharmacokinetics and Biopharmaceutics·L Z Benet
Dec 1, 1978·Journal of Pharmacokinetics and Biopharmaceutics·K YamaokaT Uno
May 1, 1990·Clinical Pharmacokinetics·L L Ponto, R D Schoenwald
Jul 22, 1988·Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character·G T McEwanM L Lucas
Dec 1, 1983·Journal of Pharmacokinetics and Biopharmaceutics·M G Lee, W L Chiou
Feb 1, 1994·Journal of Pharmaceutical Sciences·A MenonA Sakr
Dec 1, 1996·Journal of Veterinary Pharmacology and Therapeutics·J SmalI Happonen

❮ Previous
Next ❯

Citations

Feb 15, 2005·Drug Discovery Today·Stanley S Davis
Sep 8, 2010·Journal of Pharmaceutical Sciences·James M Butler, Jennifer B Dressman
Jan 17, 2016·The Journal of Pharmacy and Pharmacology·Amal A SultanGamal M El Maghraby
May 17, 2011·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Bryan LaulichtEdith Mathiowitz
Mar 18, 2003·Journal of Clinical Pharmacology·Honghui Zhou
Apr 12, 2011·Biopharmaceutics & Drug Disposition·Pius FasinuYahya E Choonara
Jul 15, 2015·Journal of Zhejiang University. Science. B·Darren S MillerRoss N Butler
Oct 11, 2017·Expert Opinion on Drug Delivery·Jin XuMatthew L Peterson
Mar 12, 2021·Expert Opinion on Drug Metabolism & Toxicology·Teruo MurakamiNicholas Bodor
Nov 5, 2019·Acta Pharmaceutica : a Quarterly Journal of Croatian Pharmaceutical Society and Slovenian Pharmaceutical Society, Dealing with All Branches of Pharmacy and Allied Sciences·Marilena VlachouAngeliki Siamidi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angelman Syndrome

Angelman syndrome is a neurogenetic imprinting disorder caused by loss of the maternally inherited UBE3A gene and is characterized by generalized epilepsy, limited expressive speech, sleep dysfunction, and movement disorders. Here is the latest research.